B. Riley Securities Maintains Buy on Journey Medical, Raises Price Target to $6
Portfolio Pulse from richadhand@benzinga.com
B. Riley Securities analyst Kalpit Patel maintains a Buy rating on Journey Medical (NASDAQ:DERM) and raises the price target from $3 to $6.
July 12, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities maintains a Buy rating on Journey Medical and raises the price target from $3 to $6. This could potentially lead to an increase in the stock's price.
The raised price target by B. Riley Securities indicates a positive outlook for Journey Medical. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100